These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38815876)

  • 1. Rediscovering immunohistochemistry in lung cancer.
    La Salvia A; Meyer ML; Hirsch FR; Kerr KM; Landi L; Tsao MS; Cappuzzo F
    Crit Rev Oncol Hematol; 2024 Aug; 200():104401. PubMed ID: 38815876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?].
    Hamard C; Mignard X; Pecuchet N; Mathiot N; Blons H; Laurent-Puig P; Leroy K; Lupo A; Chapron J; Giraud F; Arrondeau J; Goldwasser F; Alifano M; Damotte D; Wislez M
    Rev Pneumol Clin; 2018 Oct; 74(5):327-338. PubMed ID: 30343945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
    Osmani L; Askin F; Gabrielson E; Li QK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
    Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer.
    Roberts EA; Morrison LE; Behman LJ; Draganova-Tacheva R; O'Neill R; Solomides CC
    Ann Diagn Pathol; 2020 Apr; 45():151454. PubMed ID: 31923744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.
    Hung YP; Sholl LM
    Adv Anat Pathol; 2018 Nov; 25(6):374-386. PubMed ID: 30188361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
    Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
    Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
    Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy.
    Albero-González R; Munné-Collado J; Pijuan L; Simón M; Gimeno-Beltrán J; Mojal S; Salido M; Clavé S; Juanpere N; Dalmases A; Comerma L; Vázquez I; Sánchez-Font A; Taus Á; Hernández S; Lloveras B; Lloreta Trull J
    Ultrastruct Pathol; 2019; 43(6):237-247. PubMed ID: 31810413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives.
    Hofman P; Rouleau E; Sabourin JC; Denis M; Deleuze JF; Barlesi F; Laurent-Puig P
    Cancer Cytopathol; 2020 Sep; 128(9):601-610. PubMed ID: 32885912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.
    Hernandez A; Brandler TC; Chen F; Zhou F; Xia Y; Zhong J; Moreira AL; Simms A; Sun W; Wei XJ; Simsir A
    Am J Clin Pathol; 2020 Sep; 154(4):517-524. PubMed ID: 32589185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 IHC in NSCLC with a global and methodological perspective.
    Thunnissen E; de Langen AJ; Smit EF
    Lung Cancer; 2017 Nov; 113():102-105. PubMed ID: 29110835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers.
    Lambros L; Quintin-Roué I; Bourhis A; Remoué A; Le Flahec G; Marcorelles P; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):437-443. PubMed ID: 31498156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.